Switch Therapeutics
Dee is Co-Founder and CEO for Switch Therapeutics. She received her PhD from Caltech and MBA from Stanford University Graduate School of Business. Before Switch, Dee was the Chief Business Officer at XOMA. Prior to that, she served as Vice President, Corporate Development at Forty Seven, Inc., where she managed business development, strategy and company financings. Earlier in her career, she was a venture capitalist at The Column Group and Longitude Capital. As an investor, she has experience in alternative financing strategies, such as royalty monetization, in addition to formation and management of portfolio companies.
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.